AlloCure is a pioneer in the development of cell therapies for the treatment of kidney disease. The company's unique technology allows for the isolation and expansion of specific populations of mesenchymal stem cells, obtained via conventional bone marrow donation, which can then be administered in an off-the-shelf therapy to any patient in need without the need for tissue matching or immunosuppressants. The company's most advanced program, AC607, targeting acute kidney injury, is entering mid-stage clinical development and represents the first application of a stem cell therapy to alter the course of this life threatening condition.